Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas
نویسندگان
چکیده
منابع مشابه
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Recent studies have shown that there is a considerable heterogeneity in the response of melanoma cell lines to MEK and BRAF inhibitors. In the current study, we address whether dysregulation of cyclin-dependent kinase 4 (CDK4) and/or cyclin D1 contribute to the BRAF inhibitor resistance of melanoma cells. Mutational screening identified a panel of melanoma cell lines that harbored both a BRAF V...
متن کاملConjunctival melanomas harbor BRAF and NRAS mutations--Letter.
tions and similarities in chromosomal gains and losses (1). Specifically, 27% of 78 primary or locally recurrent conjunctival melanoma samples harbored a BRAF V600E mutation. Another study also demonstrated BRAF V600E mutations in 58% of conjunctival melanomas (primary and metastatic) (2). The incidence of this mutation approximates that reported in cutaneous melanoma (3). Now that two phase II...
متن کاملConjunctival melanomas harbor BRAF and NRAS mutations--response.
In our recently published study (1), we describe genetic similarities between conjunctival and cutaneousmelanoma and propose that the treatment rationale for patients with metastasized conjunctival melanoma should be adapted to that for metastasized cutaneous melanoma. Weber and colleagues (2) responded to this, reporting that a BRAF V600E–mutant metastasized conjunctival melanoma patient treat...
متن کاملVariation of mutant allele frequency in NRAS Q61 mutated melanomas
BACKGROUND Somatic mutations of BRAF or NRAS activating the MAP kinase cell signaling pathway are present in 70% of cutaneous melanomas. The mutant allele frequency of BRAF V600E (M%BRAF) was recently shown to be highly heterogeneous in melanomas. The present study focuses on the NRAS Q61 mutant allele frequency (M%NRAS). METHODS Retrospective quantitative analyze of 104 NRAS mutated melanoma...
متن کاملOvercoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
Almost 50% of metastatic melanoma patients harbor a BRAF(V600) mutation and the introduction of BRAF inhibitors has improved their treatment options. BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. However, most patients develop mechanisms of acquired resistance and abou...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Life
سال: 2021
ISSN: 2075-1729
DOI: 10.3390/life11050424